Bioanalytical Systems, Inc. Adopts InnaPhase Technology to Expedite Drug Development Services.

Business Editors/Hi-Tech Writers

PHILADELPHIA--(BUSINESS WIRE)--May 18, 2001

InnaPhase Corporation, the first and only provider of end-to-end software solutions for early drug development teams, today announced that Bioanalytical Systems, Inc. (BAS) has signed an agreement to implement InnaPhase's Watson(TM) Laboratory Information Management System (LIMS) at their West Lafayette, Indiana facility.

The Watson(TM) LIMS system is the only LIMS designed specifically to provide a protocol-driven, GLP-compliant environment that specifically supports DMPK/Bioanalytical studies in drug development. Watson maintains regulatory compliance with the FDA's 21 CFR Part 11 guidance on electronic records and signatures, and has an established track record of accelerating bioanalysis and sample management processes in drug development.

Aided by recent increases in outsourcing by many major pharmaceutical companies, contract research organizations (CRO's) have grown dramatically over the past several years and have become an increasingly important link in the drug discovery and development process.

The significant growth and competition in the outsourcing market is placing increasing pressure on CROs to provide rapid, high quality turnaround on sample and data analyses to meet customer demands.

"Many of our customers are currently using the Watson(TM) LIMS system and have been very impressed with its reporting and time-saving capabilities," said Ronald Shoup, Ph.D., president of the BAS Analytics contract services division. "By implementing Watson(TM), we anticipate general increases in productivity, more effective data exchange capabilities and a streamlined system consistent with those used within our target market."

"Many companies within the pharmaceutical industry are looking for ways to standardize their data within systems that are compliant with GxP and Part 11 guidelines," said Gary Rathsmill, senior vice president, product research of InnaPhase Corporation. "Watson(TM) LIMS allows organizations to achieve their data standardization and centralization goals and increase efficiency in the bioanalytical laboratories."

InnaPhase Corporation also develops and markets the Enterprise Pharmacology Series(TM) (EP Series(TM)), a scalable technology solution that centralizes the analysis and management of early drug development data. This protocol-driven system provides intelligent data import and export components, a flexible cross-study data-mining tool and a powerful PK/PD analysis, simulation and reporting module.

InnaPhase offers its Enterprise Pharmacology Series(TM) solution at a reduced cost for those customers that are currently utilizing Watson(TM) LIMS. When these two systems are implemented alongside each other, customers are able to take advantage of the only system that seamlessly supports early drug development from laboratory to final report.

BAS provides research and development resources to the basic research community and many of the leading pharmaceutical, medical device, animal health and biotechnology companies in the world. Since 1974 BAS has earned a worldwide reputation as an innovator in biological and chemical analysis and instrumentation.

BAS technologies are used to help detect diseases early, identify their underlying biochemistry and develop therapeutic solutions. BAS has served the pharmaceutical industry with contract services and instruments for 27 years and operates worldwide, with teams in Indiana, New Jersey, Pennsylvania, Kansas, the UK, Belgium and Japan.

InnaPhase Corporation is a worldwide leader in software technology for early drug development. Its software solutions are rapidly becoming the industry standard for pre-clinical and clinical pharmacology and help integrate early drug development data into enterprise-wide knowledge that fosters better decisions, sooner.

With 15 years of scientific experience in advanced software and clinical database technologies, InnaPhase provides solutions for more than 800 customers in 45 countries, creating a competitive edge that allows customers to maximize their drug development pipeline. InnaPhase has locations in the United States, Canada, France and the UK.

For more information, see InnaPhase on the worldwide web at www.innaphase.com.

NOTE TO EDITORS:

A complete media information kit on the EP Series and InnaPhase Corporation is available. Contact GailForce Communications at 215-238-7121.